C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
Granted 1.16M
Granted 9.5K
Granted 49.2K
Granted 435.8K
Granted 410.1K · Sold 10.0K
Granted 371.3K
Granted 318.0K · Sold 1.2K
Granted 318.0K
Granted 31.8K
Granted 92.0K
Granted 84.7K
Granted 59.8K
Granted 2.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hirsch AndrewPresident & CEO, Director · 16 transactions | +898.1% | 1.08M | 1.16M | — | — |
| Dubin GlennDirector · 3 transactions | +1.2% | 812.7Kas of Apr 2024 | 9.5K | — | — |
| Anderson Kenneth CarlDirector · 12 transactions | — | 525.4K | 49.2K | — | — |
| Adams KendraChief Financial Officer · 18 transactions | — | 400.5K | 435.8K | — | — |
| Reyno LeonardChief Medical Officer · 10 transactions | +546.6% | 396.4K | 410.1K | — | 10.0K |
| Mahaney PaigeChief Scientific Officer · 7 transactions | — | 336.9K | 371.3K | — | — |
| Boyle Scott NChief Business Officer · 18 transactions | +1115.7% | 306.1K | 318.0K | — | 1.2K |
| Schick KellyChief People Officer · 16 transactions | +1094.9% | 299.9K | 318.0K | — | — |
| Fisher StewartChief Scientific Officer · 6 transactions | +27.5% | 130.7Kas of Sep 2024 | 31.8K | — | — |
| Siegel JolieChief Legal Officer · 11 transactions | +330.1% | 107.9Kas of Feb 2025 | 92.0K | — | — |
| Mossler MarkChief Accounting Officer · 5 transactions | — | 71.9K | 84.7K | — | — |
| Grogan Donna RoyDirector · 11 transactions | +509.2% | 71.5K | 59.8K | — | — |
| White LaurenChief Financial Officer · 2 transactions | +5.1% | 32.7Kas of Aug 2023 | 2.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -11.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.